N THE UNITED STATES PATENTAND TRADEMARK OFFICE

lication No.:

10/019,094

April 12, 2002

1st Inventor:

J. Kawakami

For:

Process for the Preparation of Imidazole

Derivatives

Atty. Dkt. No.

2617 US0P

Art Unit:

Examiner:

Batch:

Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231 Sir:

> Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached form PTO-1449. A copy of the reference is enclosed.

No Final Office Action or Notice of Allowance has been mailed in this case.

This reference was cited in a European Search Report on a related application, less than three months prior to this submission. A copy of the search report is attached.

If necessary, Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a supplemental Information Disclosure Statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: December 10, 2002

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA